Opicapone: A Review in Parkinson's Disease

Area of Science:

• Pharmacology
• Neurology
• Clinical Trials

Background:

• Parkinson's disease (PD) management often involves levodopa (L-Dopa)/dopa-decarboxylase inhibitor (DDCI) therapy.
• End-of-dose motor fluctuations are a common challenge in PD patients.
• Peripheral catechol-O-methyltransferase (COMT) inhibitors offer a therapeutic strategy to manage these fluctuations.

Purpose of the Study:

• To evaluate the efficacy and safety of oral opicapone as adjunctive therapy in PD patients with motor fluctuations.
• To compare opicapone's effectiveness against placebo and entacapone in improving motor fluctuations.
• To assess the long-term safety and tolerability of opicapone.

Main Methods:

• Double-blind, multinational trials (14-15 weeks) and open-label extension studies (1 year).
• Participants received opicapone (50 mg once daily) or placebo as adjunctive therapy to L-Dopa/DDCI.
• Motor fluctuations and safety parameters were assessed throughout the study duration.

Main Results:

• Opicapone significantly improved motor fluctuations compared to placebo.
• Opicapone demonstrated non-inferiority to entacapone in managing motor fluctuations.
• Benefits were maintained during extension studies, and no new safety concerns or hepatotoxicity were reported.

Conclusions:

• Oral opicapone is an effective and well-tolerated adjunctive therapy for PD patients with end-of-dose motor fluctuations.
• Its convenient once-daily dosing makes it a valuable treatment option.
• Opicapone offers a sustained improvement in motor fluctuations without significant safety concerns.